Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04922008
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-06-10
First Post:
2021-06-07
Brief Title:
Stage I HER2 Positive Invasive Breast Cancer De-escalation StudyIRIS-CD
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
An Open-label Phase II Study Evaluating the Efficacy and Safety of Trastuzumab Combined With Oral Chemotherapy in Patients With HER-2 Positive Stage I Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy capecitabine or vinorelbine in patients with HER-2 positive stage I breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None